Dimitri Azar

Dimitri Azar is an American ophthalmologist, professor, inventor and current CEO o
Lacristat
a San Jose based ophthalmology bio-tech company. Dr. Azar previously founded Twenty Twenty Therapeutics, a joint venture established by Santen and Verily. The Twenty Twenty products were ultimately transferred to Santen and Verily in September 2024.
Azar served as a board member of Novartis and a member of the scientific advisory board of Verily, Alphabet's Life sciences research organization. He served as dean of the College of Medicine at the University of Illinois at Chicago (UIC) from 2011 to 2018, and is currently Distinguished Professor and Executive Dean Emeritus.

Education

Azar received his medical degree from the American University of Beirut, Lebanon. Azar practiced at the Wilmer Eye Institute at the Johns Hopkins Hospital School of Medicine, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School, where he was a tenured professor of ophthalmology (2003–2006) and senior scientist at the Schepens Eye Research Institute.

Azar also holds an honorary master's degree from Harvard, as well as an Executive Master of Business Administration from the University of Chicago Booth School of Business.

Academic positions

After serving as tenured professor at Harvard Medical School, Azar joined UIC as a professor of ophthalmology, bioengineering and pharmacology, where he also served as head of the Department of Ophthalmology and Visual Sciences and B.A. Field Endowed Chair of Ophthalmologic Research. He has published more than 500 scientific articles, chapters and patents with over 20,000 citations. He is a member of the American Ophthalmological Society, former president of the Chicago Ophthalmological Society, president-elect of the Chicago Medical Society, and former Trustee of the Association of Research in Vision and Ophthalmology (ARVO).

Commercial roles

Azar is the CEO o
Lacristat
a San Jose headquartered ophthalmology biotech company and serves as Senior Advisor at Verily. Until recently, he was the founder and chief executive officer of Twenty Twenty Therapeutics, a joint venture between Verily Life Sciences and Santen.

He was a non-executive member of Novartis' Board of Directors from 2012 until 2019. He was also a member of the Audit and Compliance Committee and the Research & Development Committee.

Azar was a senior director of ophthalmological innovation at Verily, where ophthalmological projects include the development of smart contact lenses, including lenses designed to assist those with presbyopia and an intraocular lens. He was on the board of Verb Surgical Inc. and sits on the board of the Tear Film and Ocular Surface Society in the US. He also sits on the board of Jellisee and the Cure Blindness Project (aka, Himalayan Cataract Project).

Published books

* Azar DT, Steinert R., Stark WJ, editors. Excimer Laser Therapy: Phototherapeutic Keratectomy Baltimore, MD: Williams & Wilkins; 1997
* Azar DT. Refractive Surgery. Stamford, CT: Appleton & Lange-Simon and Schuster; 1997
* ''Difficult and Complicated Cases in Refractive Surgery'', Jorge L. Alió and Dimitri T. Azar, Springer, 2015
* ''Pharmacologic Therapy of Ocular Disease (Handbook of Experimental Pharmacology)'', Scott M. Whitcup and Dimitri T. Azar, Springer 2017
*Albert DM, Jakobiec FA; (Azar DT, and Gragoudas ES associate editors to FAJ).  Principles and Practice of Ophthalmology Second Edition. Philadelphia, PA: Saunders; 1999.
*Jakobiec FA, Azar DT, editors. Pediatric Ophthalmology; International Ophthalmology Clinics; Winter 1992.  
*Azar DT, editor.  (Stark WJ, Azar NF, Pineda R, Yoo SH, associate editors).  Intraocular Lenses in Cataract and Refractive Surgery.  Philadelphia PA; Saunders; May 2001.
*Melki SA, Azar DT, editors.  101 Pearls in Refractive, Cataract, and Corneal Surgery.  Thorofare, NJ: Slack; June 2001.
*Azar DT, Koch DD, editors.  LASIK: Fundamentals, Surgical Techniques, and Complications.  New York, NY: Marcel Dekker; November 2002.  
*Tsubota K, Boxer-Wachler B, Azar DT, Koch DD, editors.  Hyperopia and Presbyopia.  New York, NY: Marcel Dekker; 2003.  
*Foster CS, Azar DT, Dohlman CH, editors.  Smolin and Thoft's The Cornea: Scientific Foundations and Clinical Practice, 4th Edition. Baltimore, MD: Lippincott Williams & Wilkins; 2005.  
*Azar DT, Camellin M, Yee R, editors.  LASEK, PRK, and Excimer Laser Stromal Surface Ablation.  New York, NY: Marcel Dekker; 2005.  
*Melki SA, Azar DT, editors.  101 Pearls in Refractive, Cataract, and Corneal Surgery, 2nd Edition. Thorofare, NJ: Slack; 2006.
*Azar DT, editor. (Gatinel D, Hoang-Xuan T, associate editors).  Refractive Surgery, 2nd Edition.  St. Louis, MO: Elsevier-Mosby, 2007.
*Albert DM, Miller JW, editors, Azar DT, Blodi BA, associate editors.  Albert and Jakobiec's Principles and Practice in Ophthalmology, 3rd Edition. Philadelphia, PA: Elsevier, 2008.
*Alio JL, Azar DT editors. Management of Complications in Refractive Surgery. Springer-Verlag Berlin Heidelberg, 2008.
*Azar DT, editor; BCSC 3. Clinical Optics, American Academy of Ophthalmology. San Francisco, CA; 2012.
*Alio JL, Azar DT, Abbouda A, Asward E, editors. Difficult and Complicated Cases in Refractive Surgery. Springer-Verlag Berlin Heidelberg, 2015
*Azar DT, Rosen E. Yanoff and Duke's Cataract and Refractive Surgery e-book e-book searchable.
*Whitcup S, Azar DT, editors. Pharmacologic Therapy of Ocular Disease. Springer Heidelberg, 2017
*Alio JL, Azar DT editors. Management of Complications in Refractive Surgery. Second Edition. Springer-verlap Berlin Heidelberg, 2018
*Azar DT, editor.  Refractive Surgery, 3rd Edition.  St. Louis, MO: Elsevier-Mosby, 2019.
*Azar DT, Alio JL, Hallak J, Cortina SM, editors. Surgical management of Astigmatism, Jaypee Publishing, 2020
*Albert DM, Miller JW, Azar DT, Young LH, editors, Blodi BA, associate editors. Albert and Jakobiec's Principles and Practice in Ophthalmology, 4th Edition. Philadelphia, PA: by Springer Verlag. 2022

Awards and recognition

Azar is an internationally recognized ophthalmic surgeon and prolific researcher. He has been named one of The Best Doctors in America and one of the Castle Connolly Top Doctors in America annually since 1994. He holds multiple committee positions with the American Academy of Ophthalmology, is a member of the American Ophthalmological Association and sits on the board of trustees of the Chicago Ophthalmological Society and the Association of Research in Vision and Ophthalmology. He has received multiple leadership awards, including the 2009 Lans Distinguished Award from the International Society of Refractive Surgery, and the University of Illinois at Chicago Scholar Award. Azar was awarded the Life Achievement award by the American Academy of Ophthalmology for his sustained services to the organization. The International Society of Refractive Surgery, in 2013, awarded him with the Jose Barraquer Award and has also received the University of Illinois at Chicago Scholar Award, and the Distinguished Professor award in 2013. In 2016, Weill Cornell Medical College awarded Azar with the John McLean Medal.

From 2008 to 2010, ''Chicago Magazine'', in cooperation with Castle Connelly Medical Ltd., listed Azar as one of the top doctors in ophthalmology. In 2016, he received the Castroviejo Award in recognition of exceptional contributions in support of the Society's mission from the American Academy of Ophthalmology, as well as the Ramon Castroviejo Award from the Cornea Society. On June 27, 2019, he received an honorary doctoral degree from the University of Balamand, in recognition of his significant lifetime achievements as a world-renowned scholar, creative inventor, academician, and eye surgeon.

Other notable awards

External links

Novartis profile


UIC statement

References

{{DEFAULTSORT:Azar, Dimitri
1959 births
Living people
Eye care in the United States
American University of Beirut alumni
University of Chicago faculty
Harvard Medical School people
Lebanese ophthalmologists